Lucas K H, Kaplan-Machlis B
Department of Clinical Pharmacy, West Virginia University, Charleston, USA.
Ann Pharmacother. 2001 Mar;35(3):314-28. doi: 10.1345/aph.19412.
To review the pharmacology, pharmacokinetics, clinical safety and efficacy, drug interactions, and therapeutic issues related to the use of orlistat for treatment of obesity.
English-language articles were identified from MEDLINE (1966-July 2000), Roche Laboratories, organizational guidelines, National Institutes of Health and Food and Drug Administration Web sites, and Doctor's Guide online. Key words included obesity, orlistat, and lipase inhibitors. References were also identified from reference sections of published articles.
Prospective, randomized, double-blind, placebo-controlled, human trials were selected for review and discussion.
Orlistat is the first agent in the lipase inhibitor class of antiobesity drugs. Orlistat is minimally absorbed and has been shown to reduce body weight by inhibiting absorption (by approximately 30%) of ingested dietary fat. Safety and efficacy have been established in one- and two-year double-blind, placebo-controlled trials; adverse effects were primarily, and almost exclusively, gastrointestinal. Due to its ability to block fat absorption, orlistat also has the capability to inhibit absorption of fat-soluble vitamins. Therefore, a daily multiple vitamin is recommended while taking orlistat.
By inhibiting fat absorption, orlistat offers a new treatment modality for weight loss and maintenance. Preliminary data from clinical trials suggest that orlistat may be beneficial in patients with comorbid conditions related to obesity, such as diabetes and hyperlipidemia. However, further studies during postmarketing surveillance are needed to fully establish orlistats long-term benefits and safety. Orlistat should be considered a useful adjunctive therapy for weight loss and maintenance in obese patients (i.e., body mass index > or = 30 kg/m2 or > or = 27 kg/m2 if other risk factors are present) committed to lifestyle changes including diet, exercise, and behavioral modification.
综述奥利司他用于治疗肥胖症的药理学、药代动力学、临床安全性与有效性、药物相互作用以及治疗相关问题。
从MEDLINE(1966年至2000年7月)、罗氏实验室、组织指南、国立卫生研究院及食品药品管理局网站以及在线医生指南中检索英文文章。关键词包括肥胖症、奥利司他和脂肪酶抑制剂。还从已发表文章的参考文献部分获取参考文献。
选择前瞻性、随机、双盲、安慰剂对照的人体试验进行综述与讨论。
奥利司他是抗肥胖药物脂肪酶抑制剂类中的首个药物。奥利司他极少被吸收,已证明可通过抑制摄入膳食脂肪的吸收(约30%)来减轻体重。在为期一年和两年的双盲、安慰剂对照试验中已确立其安全性和有效性;不良反应主要且几乎仅为胃肠道反应。由于其阻断脂肪吸收的能力,奥利司他也有抑制脂溶性维生素吸收的能力。因此,服用奥利司他时建议每日补充多种维生素。
通过抑制脂肪吸收,奥利司他为减肥和维持体重提供了一种新的治疗方式。临床试验的初步数据表明,奥利司他可能对患有与肥胖相关的合并症(如糖尿病和高脂血症)的患者有益。然而,需要在上市后监测期间进行进一步研究,以充分确立奥利司他的长期益处和安全性。对于致力于包括饮食、运动和行为改变在内的生活方式改变的肥胖患者(即体重指数≥30 kg/m²或若存在其他危险因素则≥27 kg/m²),奥利司他应被视为减肥和维持体重的有用辅助治疗药物。